41例可手术多原发肺癌临床分析

doi:10.3969/j.issn.1007-3969.2014.09.010

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (9): 700-706.doi: 10.3969/j.issn.1007-3969.2014.09.010

41例可手术多原发肺癌临床分析

李营¹,金波¹,施建新²,张岩巍¹,吉春宇²,韩宝惠¹

1.上海交通大学附属胸科医院呼吸内科，上海 200030 ；
2.上海交通大学附属胸科医院胸外科，上海 200030

出版日期:2014-09-30 发布日期:2014-11-12
通信作者: 韩宝惠　E-mail:xkyyhan@gmail.com
基金资助:
上海市自然科学基金资助(No：13ZR1438600)

Clinical analysis of 41 cases with resected multiple primary lung cancers

LI Ying¹, JIN Bo¹, SHI Jianxin²,ZHANG Yan-wei¹, JI Chun-yu², HAN Bao-hui¹

1.Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China; 2. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China

Published:2014-09-30 Online:2014-11-12
Contact: HAN Bao-hui E-mail: xkyyhan@gmail.com

摘要/Abstract

摘要：

背景与目的：多原发肺癌(multiple primary lung cancers，MPLC)是原发性肺癌中的一种少见类型，但近年临床检出率呈逐渐升高的趋势。本研究对41例MPLC的临床资料进行总结分析，进一步探讨MPLC的诊断、治疗和预后。方法：参照Martini-Melamed诊断标准，对41例MPLC的临床病理资料进行回顾性分析。结果：41例患者中三原发肺癌3例，双原发肺癌38例。同时性MPLC13例，异时性MPLC26例，同时性MPLC+异时性MPLC2例。手术方式以肺叶切除为主(78.8%，67/85)，病灶好发于右上叶(41.2%，35/85)，病理以腺癌多见(70.6%，60/85)，其次为鳞癌(17.6%，15/85)。腺癌亚组中以乳头状为主的病理亚型比率较高(50%，30/60)。分期以I期为主(80%，68/85)。组织病理类型相同的MPLC比例(68.3%，28/41)高于不同病理类型(31.7%，13/41)，其中腺癌-腺癌多见(82.1%，23/28)。病灶位于同侧不同肺叶者4例(9.8%)，位于双侧肺者37例(90.2%)。MPLC2年总生存(overall survival，OS)率为87.8%(36/41)，生存分析显示病理类型相同组较不同组预后好(P=0.037)，无淋巴结转移的MPLC较有淋巴结转移组预后好(P=0.02)。结论：MPLC病灶好发于右上叶，病理以腺癌最常见，乳头状为主的病理亚型多见。其早期检出率越来越高，采取积极的手术治疗可获得较为理想的预后。

关键词: 多原发肺癌, 三原发肺癌, 双原发肺癌, 腺癌, 总生存期

Abstract:

Background and purpose: Multiple primary lung cancers (MPLC) is a rare entity, but recently there has been a gradual increase in the number of patients diagnosed with MPLC. The aim of this study is to investigate the diagnosis, treatment and prognosis of MPLC through analyzing the clinical data. Methods: Forty-one patients were diagnosed MPLC by Martini-Melamed criteria. Their clinicopathological data were retrospectively reviewed. Results: There were 3 patients with triple primary lung cancer and 38 patients with double primary lung cancer. There were 13 patients with synchronous MPLC, 26 patients with metachronous MPLC, 2 patients with synchronous and metachronous MPLC. Of 85 lesions, the surgical procedures were mainly lobectomy (78.8%, 67/85). Lesions (41.2%, 35/85) were frequently in right upper lobe. Pathological type was mainly adenocarcinoma (70.6%, 60/85), followed by squamous cell carcinoma (17.6%, 15/85). Of 60 adenocarcinoma specimens, the papillary predominant subtype was more common (50%, 30/60). Eighty percent (68/85) of the lesions were stage I. As to the initial cancer and repeated cancer, patients who shared the same pathological type (68.3%, 28/41) were more than the different (31.7%, 13/41), of which adenocarcinoma-adenocarcinoma was most common(82.1%, 23/28). Lesions located in contralateral lobes were in 37 patients (90.2%), and located in ipsilateral different lobes were in 4 patients (9.8%). The 2-year overall survival (OS) of them was 87.8%. Survival analysis showed that the prognosis of patients with same pathological type was better than patients with different pathological type (P=0.037), the prognosis of patients with no lymph node metastasis was better than patients with N1, N2 metastasis (P=0.02). Conclusion: Lesions in patients with multiple primary lung cancers are more frequently in the right upper lobes. The pathology type is mainly adenocarcinoma, of which the papillary predominant subtype was most common. Early diagnosis improves continuously, active treatment with operation can achieve better prognosis.

Key words: Multiple primary lung cancers, Triple primary lung cancer, Double primary lung cancer, Adenocarcinoma, Overall survival

李营,金波,施建新,张岩巍,吉春宇,韩宝惠. 41例可手术多原发肺癌临床分析[J]. 中国癌症杂志, 2014, 24(9): 700-706.

LI Ying, JIN Bo, SHI Jianxin,ZHANG Yan-wei, JI Chun-yu, HAN Bao-hui. Clinical analysis of 41 cases with resected multiple primary lung cancers[J]. China Oncology, 2014, 24(9): 700-706.

[1]	朱鑫哲, 李浩, 徐华祥, 罗国培, 虞先濬. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022, 32(1): 1-12.
[2]	章箎, 陈佳慧, 林瑾仪, 王妍, 张斯加, 朱玮, 程蕾蕾. 一种新型《乳腺癌治疗相关心血管毒性临床评分表》的价值分析[J]. 中国癌症杂志, 2022, 32(1): 54-60.
[3]	金奕滋, 林明曦, 张剑. DNA损伤应答缺陷作为乳腺癌治疗靶点的研究进展[J]. 中国癌症杂志, 2022, 32(1): 61-67.
[4]	徐文浩, 田熙, 艾合太木江·安外尔, 瞿元元, 施国海, 张海梁, 叶定伟. 人工智能在泌尿系统肿瘤中的应用研究进展[J]. 中国癌症杂志, 2022, 32(1): 68-74.
[5]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[6]	张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.
[7]	曹爱玲, 曹　喆, 周　剑. 多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究[J]. 中国癌症杂志, 2021, 31(9): 799-806.
[8]	姚　嘉, 李冠乔, 杨时平, 苏慧銮 . Hsa-miR-98-5p/DKK3信号轴对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2021, 31(9): 807-816.
[9]	彭　辉, 张志发, 朱贤强, 张潇涵, 秦海丽 . 结直肠腺癌差分化细胞群与临床病理学参数的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 817-821.
[10]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[11]	杨士鹏, 刘颖, 王馨悦, 杨洋, 全吉淑, 林贞花 . PKLR在胰腺癌中的表达水平及临床病理学意义[J]. 中国癌症杂志, 2021, 31(8): 704-713.
[12]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[13]	韦　煜, 张挺维, 何　屹, 李　俊, 毕建斌, 曾　宇, 万里军, 吴高亮, 王焕昇, 张　军, 朱　崴, 瞿元元, 朱　耀, 叶定伟 . 氟唑帕利治疗转移性去势抵抗性前列腺癌的初步有效性及安全性研究[J]. 中国癌症杂志, 2021, 31(7): 561-566.
[14]	丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
[15]	金优萍, 李录英, 周　平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.

41例可手术多原发肺癌临床分析

Clinical analysis of 41 cases with resected multiple primary lung cancers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价